Skip to content

Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant

Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01239472
Enrollment
30
Registered
2010-11-11
Start date
2011-01-31
Completion date
2015-06-30
Last updated
2020-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunosuppression, Renal Transplant Rejection

Keywords

chronic allograft nephropathy, cytokines, kidney transplant, calcineurin inhibitors withdrawn

Brief summary

Currently, acute kidney injury is diagnosed by increased serum creatinine. However, creatinine is not a reliable marker for acute changes in renal function. The biology of the renal graft is influenced by chemokines from reperfusion (just after the kidney transplant) and throughout its course, when acute and chronic inflammatory changes occurs. Moreover, the evaluation of changes in urinary cytokines reflects kidney interstitial patterns, and can predict renal function, acute rejection episodes and their response to treatment. Today there are several studies comparing the relative immunosuppression of renal function, but few noticed its relationship with cytokines and chemokines. Thus, we proposed studying the inflammatory consequences of early calcineurin inhibitors (ICN) withdrawing in transplant patients by urine analysis. Kidney biopsy was done before ICN withdrawn and replaced by everolimus (3 months after transplant), and 1 year after transplant.

Detailed description

1. Research objectives OBJECTIVES Main Objectives: • Evaluate the urinary chemokines in kidney transplant patients taking prednisone, tacrolimus and mycophenolate sodium compared to those in use prednisone, mycophenolate sodium and everolimus as maintenance immunosuppression. Secondary Objectives: • Assess renal function (serum creatinine and its clearance estimated by the Cockcroft-Gault) and a composite outcome (acute rejection, graft loss, death and abandonment of the study) in patients taking prednisone, tacrolimus and mycophenolate sodium compared to those taking prednisone, mycophenolate sodium and everolimus as maintenance immunosuppression. 2. Scientific background, relevance and justification of the research In current clinical practice, acute kidney injury is typically diagnosed by measuring serum creatinine. Unfortunately, creatinine is an unreliable indicator during acute changes in kidney function. First, serum creatinine concentrations may not change until about 50% of kidney function has already been lost. Second, serum creatinine does not accurately depict kidney function until a steady state has been reached, which may require several days. Chemokines can influence at least three aspects of the biology of the renal graft: 1 - the restoration of blood flow in the graft can lead to injury type ischemia / reperfusion in which chemokines recruit leukocytes; 2 - receptor responses to infection during immune suppression involve chemokines and 3 - the inflammatory components in the acute rejection (RA) and interstitial fibrosis / tubular atrophy (IF/TA) are controlled by chemokines. Current data have showed urinary cytokines predicting renal function by months in renal transplanted patients. In the evaluation of urinary cytokines and chemokines in the presence of acute rejection, taken together the studies reported elevations of urinary levels of Protein-3 alpha (MIP-3α/CCL20), interleuxin-8 (IL-8/CXCL8), interleuxin-6 (IL-6), tumoral necrosis factor (TNF), interleukin- 10 (IP-10), interferon (IFN), monocyte chemoattractant protein-1 (MCP-1 / CCL2), Interferon gamma-induced protein 10 (IL-10), Monokine induced by gamma interferon (MIG/CXCL9), Interferon-inducible T-cell alpha chemoattractant (I-TAC/CXCL11), regulated upon activation normal T cell expressed and secreted (RANTES/CCL5). As predictors of complications and future changes in renal function, levels of Transforming growth factor beta (TGF-β) and interferon-gamma inducible protein 10 (IP-10/CXCL10) were associated with renal function 6 months and 4 years after transplantation (15-16). IP-10/CXCL10, MIG/CXCL9, G protein-coupled receptor 9 (GPR9/CXCR3), RANTES/CCL5 and the percentage of binding of interleukin-2 (IL-2) were associated with the occurrence of RA. IP-10/CXCL10 and MIG/CXCL9 were also considered useful as predictors of response to treatment of RA. Nankivell et al reported in 2003 that after 1year of renal transplant, 94% of patients present with chronic rejection grade I (BANFF score) and 76% present with calcineurin nephrotoxicity, although there is insufficient data about urinary cytokines at these situations. And adding new information, Hu et al reported in 2009 urinary major intrinsic protein-delta (MIP-δ), osteoprotegerin (OPG), IP-10/CXCL10, MIG/CXCL9 as good biomarkers for acute renal rejection and IF/TA. Nowadays there is a lot of studies comparing immunosuppression in relation to renal function but not so much in relation to chemokines and cytokines, which are more representative of allograft inflammation and fibrosis. So, we proposed studying the inflammatory consequences of early CNI withdrawn in renal transplant patients before the immunosuppression modification (3 months after transplant) and 1 year after kidney transplant.

Interventions

DRUGEverolimus

Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.

Sponsors

Novartis
CollaboratorINDUSTRY
Andre Barreto Pereira
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years old and under 65 years old * Recipients of first kidney transplant * Donor younger than 65 years old * PRA (panel reactive antigen) ≤ 30% in class I or class II * No acute rejection episodes * Proteinuria \<1000 mg / day

Exclusion criteria

* multiple organ transplant recipient * Chronic liver failure * Asymptomatic bacteriuria or urinary infection at randomization time * Creatinine ≥ 2 mg / dL at randomization time (90 days after transplant) * Presence of uncontrolled hypercholesterolemia (≥ 350 mg / dL, ≥ 9.1 mmol / L) or hypertriglyceridemia (≥ 500 mg / dL, ≥ 5.6 mmol / L) at randomization time (90 days after transplant)

Design outcomes

Primary

MeasureTime frameDescription
Cytokines EvaluationUrine and biopsy data are collected 90 days and 365 days after transplant.Cd106(VCAM-1) , IP-10/CXCL10, MIG/CXCL9, MCP-1/CCL2, IL-1, RANTES, IL-8, IL12p70, TNF, IL-10, IL-6, IL-1, VEGF, FGF, CD54(ICAM-1) were analysed in urine 90 days after transplant (before randomization), and 365 days after transplant. Material were conserved at -80 Celsius, and analysed by ELISA at same time. Data was shown in MFI units

Secondary

MeasureTime frameDescription
Evaluation of Renal Function90 days after transplant and 365 days after transplantEvaluation of renal function (serum creatinine) 90 days after transplant and 365 days after transplant.

Countries

Brazil

Participant flow

Participants by arm

ArmCount
Tacrolimus
Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone with low immunologic risk .
10
Everolimus
Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone with low immunologic risk, and converted for use of mycophenolate sodium, everolimus, and prednisone after 90 days of kidney transplantation.
12
Total22

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event01
Overall StudyLack of Efficacy01
Overall StudyWithdrawal by Subject51

Baseline characteristics

CharacteristicTacrolimusEverolimusTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
10 Participants12 Participants22 Participants
Region of Enrollment
Brazil
10 participants12 participants22 participants
Sex: Female, Male
Female
5 Participants6 Participants11 Participants
Sex: Female, Male
Male
5 Participants6 Participants11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 150 / 15
other
Total, other adverse events
0 / 151 / 15
serious
Total, serious adverse events
0 / 151 / 15

Outcome results

Primary

Cytokines Evaluation

Cd106(VCAM-1) , IP-10/CXCL10, MIG/CXCL9, MCP-1/CCL2, IL-1, RANTES, IL-8, IL12p70, TNF, IL-10, IL-6, IL-1, VEGF, FGF, CD54(ICAM-1) were analysed in urine 90 days after transplant (before randomization), and 365 days after transplant. Material were conserved at -80 Celsius, and analysed by ELISA at same time. Data was shown in MFI units

Time frame: Urine and biopsy data are collected 90 days and 365 days after transplant.

Population: 15 patients were enrolled in each group. However in tacrolimus group 5 patients didn't want to be submitted to other biopsy and to collect urine 365 days after transplant. And in everolimus group 3 patients had adverse events and was switched back to tacrolimus.

ArmMeasureGroupValue (MEDIAN)
TacrolimusCytokines EvaluationIL10 90days155 MFI
TacrolimusCytokines EvaluationIP10 90days380 MFI
TacrolimusCytokines EvaluationIL10 365 days179 MFI
TacrolimusCytokines EvaluationMIG 90days396 MFI
TacrolimusCytokines EvaluationIL6 90days282 MFI
TacrolimusCytokines EvaluationIL8 365days641 MFI
TacrolimusCytokines EvaluationIL6 365days281 MFI
TacrolimusCytokines EvaluationMIG 365days287 MFI
TacrolimusCytokines EvaluationIL1 90days212 MFI
TacrolimusCytokines EvaluationIP10 365days763 MFI
TacrolimusCytokines EvaluationIL1 365days228 MFI
TacrolimusCytokines EvaluationRANTES 90days148 MFI
TacrolimusCytokines EvaluationVEGF 90days82 MFI
TacrolimusCytokines EvaluationIL12 365days124 MFI
TacrolimusCytokines EvaluationVEGF 365days84 MFI
TacrolimusCytokines EvaluationRANTES 365days144 MFI
TacrolimusCytokines EvaluationFGF 90days39 MFI
TacrolimusCytokines EvaluationMCP1 90days2349 MFI
TacrolimusCytokines EvaluationFGF 365days30 MFI
TacrolimusCytokines EvaluationTNF 90days136 MFI
TacrolimusCytokines EvaluationCD106 90days43222 MFI
TacrolimusCytokines EvaluationIL12 90days116 MFI
TacrolimusCytokines EvaluationCD106 365days18324 MFI
TacrolimusCytokines EvaluationTNF 365days153 MFI
TacrolimusCytokines EvaluationCD54 90days1512 MFI
TacrolimusCytokines EvaluationMCP1 365days1306 MFI
TacrolimusCytokines EvaluationCD54 365days696 MFI
TacrolimusCytokines EvaluationIL8 90days495 MFI
EverolimusCytokines EvaluationCD54 365days1664 MFI
EverolimusCytokines EvaluationIL8 90days624 MFI
EverolimusCytokines EvaluationIL8 365days435 MFI
EverolimusCytokines EvaluationIL12 90days124 MFI
EverolimusCytokines EvaluationIL12 365days124 MFI
EverolimusCytokines EvaluationIP10 90days893 MFI
EverolimusCytokines EvaluationIP10 365days147 MFI
EverolimusCytokines EvaluationMCP1 90days4119 MFI
EverolimusCytokines EvaluationMCP1 365days1375 MFI
EverolimusCytokines EvaluationMIG 90days433 MFI
EverolimusCytokines EvaluationMIG 365days580 MFI
EverolimusCytokines EvaluationRANTES 90days145 MFI
EverolimusCytokines EvaluationRANTES 365days155 MFI
EverolimusCytokines EvaluationTNF 90days146 MFI
EverolimusCytokines EvaluationTNF 365days157 MFI
EverolimusCytokines EvaluationIL10 90days164 MFI
EverolimusCytokines EvaluationIL10 365 days182 MFI
EverolimusCytokines EvaluationIL6 90days349 MFI
EverolimusCytokines EvaluationIL6 365days262 MFI
EverolimusCytokines EvaluationIL1 90days215 MFI
EverolimusCytokines EvaluationIL1 365days228 MFI
EverolimusCytokines EvaluationVEGF 90days70 MFI
EverolimusCytokines EvaluationVEGF 365days45 MFI
EverolimusCytokines EvaluationFGF 90days43 MFI
EverolimusCytokines EvaluationFGF 365days29 MFI
EverolimusCytokines EvaluationCD106 90days28564 MFI
EverolimusCytokines EvaluationCD106 365days19614 MFI
EverolimusCytokines EvaluationCD54 90days1293 MFI
p-value: <0.05Wilcoxon (Mann-Whitney)
Secondary

Evaluation of Renal Function

Evaluation of renal function (serum creatinine) 90 days after transplant and 365 days after transplant.

Time frame: 90 days after transplant and 365 days after transplant

ArmMeasureGroupValue (MEDIAN)
TacrolimusEvaluation of Renal FunctionCr 365days1.4 mg/dL
TacrolimusEvaluation of Renal FunctionCr 90days1.6 mg/dL
EverolimusEvaluation of Renal FunctionCr 90days1.3 mg/dL
EverolimusEvaluation of Renal FunctionCr 365days1.4 mg/dL
p-value: <0.05Wilcoxon (Mann-Whitney)

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026